Ceapro Inc. to Provide a Corporate Update at Its Annual General and Special Meeting of Shareholders on May 29, 2018

EDMONTON, ALBERTA – May 24, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will provide a corporate update to on-site shareholders on Tuesday, May 29, 2018 at 8:30 a.m. MDT at the Westin Hotel, Edmonton, AB. Mr. Gagnon’s presentation will be followed by the Annual General and Special Meeting of Shareholders to be held at 10:00 a.m. MDT in the Centennial Room of the Westin Hotel. Shareholders are invited to breakfast, which will begin at 7:30 a.m. MDT.

As part of his presentation, Mr. Gagnon will provide a corporate overview and an update on the Company’s de-risked cosmeceuticals business. Mr. Gagnon will also discuss the Company’s long-term strategic vision of leveraging its two pharmaceutical-grade active ingredient value drivers, avenanthramides and beta glucan, and their development into different formulations to enable the transition into the high-value nutraceutical and pharmaceutical sectors.

The presentation used during Mr. Gagnon’s prepared remarks for the corporate update will be made available on the Company’s website (www.ceapro.com) on May 29, 2018.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to download a PDF of this press release.